Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Environmental factors and exposure to toxins may contribute to male infertility by affecting sperm and hormone function.

This study indicates that insulin changes sex hormone levels in insulin-resistant women with polycystic ovary syndrome without affecting gonadotropin release, challenging the idea that hyperinsulinemia directly causes hyperandrogenism in PCO.

This study found that long-term GnRH agonist administration in premenopausal women with polycystic ovarian disease resulted in persistent suppression of ovarian steroid secretion, while adrenal steroid levels remained unchanged.

In this study, significant elevations of DHA and testosterone were associated with pubic hair development and voice changes in boys during puberty.

This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.

This study found that nafarelin treatment significantly reduced androgen levels and improved hirsutism symptoms in women, suggesting it may be useful for managing this condition.

This study found that combining a GnRH agonist with a low-dose oral contraceptive was more effective in treating hirsutism than either agent alone and prevented hypoestrogenic side effects.

This study found that women with PCOS who have an exaggerated 17-hydroxyprogesterone response to buserelin exhibit more severe hyperandrogenemia, increased insulin secretion, and reduced insulin sensitivity.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

This study found that the LH response to nafarelin effectively distinguished gonadotropin deficiency from constitutional delay of puberty, performing comparably to the sleep test and offering certain advantages.

This study found that three months of oral finasteride treatment significantly decreased dihydrotestosterone levels and hair growth in hirsute women without negatively affecting gonadotropin secretion.

This case study details a 57-year-old woman with symptoms of androgen excess, including rapid hair growth and temporal balding, alongside abnormal testosterone levels and a history of chronic renal failure.

This study found that treatment with a GnRH agonist and estrogen and progestin replacement significantly improved hirsutism scores and hair growth rates in women with polycystic ovarian disease.

This study found that GnRH agonist treatment improved hirsutism scores more than finasteride after six months in women with idiopathic hirsutism, with both treatments causing no menstrual abnormalities or side-effects.

This study concluded that a regimen of transdermal estradiol and oral medroxyprogesterone acetate effectively reduces hirsutism while minimizing side effects in women with polycystic ovary syndrome.

In this case report, goserelin, a GnRH agonist, was effective in managing stuttering priapism and improving erectile function in a patient with sickle cell disease, suggesting potential for last-line treatment.

This study found that a nomogram prediction model based on clinical characteristics, bone metabolism, and ovarian function can effectively predict the treatment response to long-acting GnRHa in girls with idiopathic central precocious puberty.

This meta-analysis found that while both Dienogest and GnRH analogues effectively managed endometriosis-related pain, Dienogest reduced recurrence rates and hot flushes but increased irregular bleeding, making it a safer option due to fewer side effects.

This study found that lowering serum DHT levels with 5 mg finasteride daily did not significantly alter serum gonadotropin levels in healthy young men after 28 days.

This case report describes a 36-year-old woman experiencing telogen effluvium, noting her recent rapid weight loss and injections of chorionic gonadotropin as potential contributing factors.

This review discusses therapeutic options for pubertal induction in congenital hypogonadotropic hypogonadism, focusing on recombinant gonadotropins, and highlights the need for larger randomized trials to determine optimal treatment strategies.

In this correspondence, an observed pattern of significant hair shedding occurred four to six weeks after women discontinued chorionic gonadotropin and a 400-calorie diet, ruling out other common causes of telogen effluvium.

Low-dose gonadotropin treatment is effective for infertility in women with PCOS, leading to high ovulation rates and comparable pregnancy rates with fewer complications.

This study found that hCG decreased 5α-reductase and androgen receptor levels in skin samples from women in vitro, suggesting that human skin responds to LH/hCG treatment.

This article discusses the role of suction-assisted lipectomy (SAL) and the hCG method in obesity management, highlighting the speculative benefits of hCG but reporting no new clinical findings.

In this study, women with a complete hydatidiform mole had significantly higher pre-evacuation levels of hCG, free testosterone, and DHEA-S compared to controls, which declined after HM evacuation.

This study found that both Clomiphene Citrate and Human Chorionic Gonadotropin were effective in restoring testosterone levels in men with hypogonadism, as demonstrated in a short-course randomized study.

This study found that low doses of leuprolide effectively suppressed serum estradiol and LH response, while higher doses were needed to suppress testosterone and reduce hair growth in hirsute women.

This report details the clinical presentation of an 18-year-old female with Kallmann syndrome, noting her ocular issues and differences in sexual development. The researchers treated her eye conditions cosmetically with superficial keratectomy and amniotic membrane graft, followed by corneal tattooing and strabismus correction.